Anzeige
Mehr »
Login
Montag, 29.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Basin Uranium: Es geht los! Der Uran-Superzyklus ist gestartet!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
21 Leser
Artikel bewerten:
(0)

Congestive Heart Failure - Pipeline Analysis



DUBLIN, July 15, 2015 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/gtpmcn/congestive_heart) has announced the addition of the "Congestive Heart Failure - Pipeline Analysis" report to their offering.

"Congestive Heart Failure (CHF) Pipeline Analysis gives comprehensive insight on the various drugs being developed for the treatment of CHF. The report covers all the drugs being developed in various development phases (Discovery to Phase 2 clinical). The pipeline focuses on disease modification and includes pharmacologic drugs, gene therapy, stem cell therapy and RNA-based therapeutics, but excludes symptom relief drugs like diuretics, acute treatments, angiotensins or thrombin inhibitors etc. The report also covers some of the hot targets in research for CHF treatments.

This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative opportunities in the CHF Drug market. The report also provide strategic insights on medicines that are likely to have an impact on CHF treatment space and potentially alter standards of care in CHF in the foreseeable future.

Current therapies focuses only to slow down the progression of the disease as more number of molecules are symptom relieving drugs, hence it provides a tremendous opportunity for upcoming therapies specific to CHF such as gene-based, stem cell-based and miRNA-based therapies, which reverses disease course and reduce the number of cardiac events.

Key Topics Covered:

1. Report Description

2. Introduction - Causes & Symptoms - Diagnosis - Classification - Compensatory mechanisms - Unmet needs

3. Epidemiology

- Prevalence

- Incidence

- Hospitalizations

- Re-admissions

4. Market Data - Forecasting model - Market dynamics - Market sizing - Cost burden

5. Pipeline Analysis

- Development stage

- Modalities

- Leading players

- Innovative approaches

- Associated targets

6. Genetherapy - Pipeline - Competitive landscape

7. Stemcell Therapy

- Pipeline

- Competitive landscape

8. RNA Based Therapeutics - mi-RNA - m-RNA - Pipeline - Competitive landscape

9. Drugs (small molecules, recombinant proteins, growth factors)

- Pipeline

- Competitive landscape

10. Hot Targets in Research Major Players - Company Profiles - Overview, Pipeline & Deals

11. References

Companies Mentioned

- Bayer Ag

- Bioheart, Inc.

- Celladon Corp

- Coretherapix

- Glaxosmithkline

- Juventas Therapeutics

- Merck & Co.

- Miragen Therapeutics

- Moderna Therapeutics

- Nano Cor Therapeutics

- Ono Pharmaceuticals

For more information visit http://www.researchandmarkets.com/research/gtpmcn/congestive_heart

Media Contact:

Laura Wood, +353-1-481-1716, press@researchandmarkets.net



Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2015 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.